A Phase II, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy

This study is evaluating a new drug for the treatment of IgA Nephropathy

Primary Sponsor:
MD Serono Research & Development Institute, Inc. (US)

Prinicipal Investigator:
Dr. Scott Cohen/Nephrology

Contact Phone:
202-741-3047

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):